Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2845)	5/17/2010 2:17:54 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

NBIX was up 9.22% and is still up 4.06% on volume of > 182K >0.5x its ADV The stock tried again to go over the resistance at the $3 level.<g> bigcharts.marketwatch.com NBIX has trimmed its losses for the las 4Qs. The total loss last Yr. was $1.18 vs. $1.83 in 2008. For 2010 the EL is around $0.60 It reportedly had $69.2 in csh as of March 31, vs. $59.9M in Dec. The increase in cash includes a $21.4M raised in a 10.5M shrs offering that was completed in March. <g> NBIX has several irons on the fire.<g> It expects that its four clinical programs continue on track and each one will come out with important data over the next nine to twelve months.<g> They are expecting to be able to report data from their elagolix Daisy PETAL study by the end of this month. The blinded treatment portion of the Daisy PETAL has been completed and the open label extension portion of the trial is proceeding well. Elagolix is its main drug, with good potential for treatment of dysmenorrhea in patients with endometriosis. Another drug in its pipeline, urocortin 2 NBIX in collaboration with the Christchurch Cardioendocrine Research Group at Univ. of Otago, and Christchurch School of Medicine and Health Sciences, New Zealand is enrolling patients with Acute Decompensated Heart Failure in a study of urocortin 2. Urocortin 2 will also be studied by the Centre for Cardiovascular Sciences at The Univ. of Edinburgh through a British Heart Foundation grant. Nine studies will be conducted this Yr. in both healthy volunteers and patients with stable congestive heart failure to determine the impact of urocortin 2 infusions on biomarkers of CHF. Its VMAT2 is to expected to complete a repeated PI in healthy male volunteers, and then initiate a proof-of-concept study in patients with tardive dyskinesia later this Yr. Its Corticotropin Releasing Factor,CRF1 Receptor Antagonists, in collaboration with GSK, has identified multiple unique high affinity and selective antagonists for the CRF1 receptor that are currently in development for mood disorders and irritable bowel syndrome. GSK is running a multicenter randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of 561679 in approximately 150 subjects with Major Depressive Disorder over six weeks of treatment. This study is scheduled to be completed in June. Emory University and Mt. Sinai Medical Center in N.Y., in conjunction with GSK, have also started recently a second PII to evaluate 561679 in women with post-traumatic stress disorder. However, the results of that study will not be available for some time, as it will probably take several years.<g> The ACTAY is $3.75 The stock needs to close above its Apr22H of $3.51 in order to get off from its medium term DT coming from the Sep2008 H at $6.05 bigcharts.marketwatch.com And it needs to close above its Feb2007 H of $14.88 in order to cut some of its rather fast drop in March-June 2006 from $73.13 to $8.61 <g> bigcharts.marketwatch.com It seems better to wait and see if the stock can close above the $3 level.<g> Bernard